RLF.SW stock CHF 2.885 intraday 06 Apr 2026: earnings catalysts to watch

RLF.SW stock trades at CHF 2.885 intraday on the SIX in Switzerland as investors position ahead of the company’s upcoming earnings announcement on 08 Apr 2026. Volume is elevated at 66,704.00 shares versus a 50-day average of 41,210.00, signalling trader interest. Relief Therapeutics Holding AG faces clinical milestones that could move the stock, and today’s price sits between the 50-day average CHF 2.9113 and the 200-day average CHF 2.6056.

RLF.SW stock earnings timetable and immediate catalysts

Relief Therapeutics (RLF.SW) reports on 08 Apr 2026, making near-term reaction likely. Key catalysts are trial updates for RLF-100 (aviptadil) and any commentary on cash runway or partner deals. For company materials and recent press, see the official site Relief Therapeutics website and the investor news page Relief Therapeutics investor news.

Intraday price action and market context for RLF.SW stock

The stock opened at CHF 2.87 and is trading in a CHF 2.80–3.00 range today. Market cap is CHF 36,280,179.00 and shares outstanding are 12,575,452.00, so single announcements can shift price materially. Healthcare sector performance is negative YTD versus peers; investors should weigh sector pressure against company-specific trial news. For live quotes and historical trades, see our platform Meyka RLF.SW page.

Fundamentals, valuation and financial metrics

Relief’s trailing EPS is -1.36 and the PE ratio is -2.12, reflecting losses typical for clinical-stage biotech. Price-to-book is 1.11 and cash per share is 0.99, supporting a current ratio of 4.05. Revenue per share is 0.32, price-to-sales is 8.95, and EBITDA multiples are distorted by negative earnings. These metrics show a company still in R&D and not yet cash-flow positive.

Meyka AI rates RLF.SW with a score out of 100

Meyka AI rates RLF.SW with a score of 64.81 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights moderate upside from clinical progress but elevated risk from negative EPS and valuation. These grades are not guaranteed and we are not financial advisors.

Meyka AI forecast model and implied upside

Meyka AI’s forecast model projects CHF 1.7285 for 1 year, CHF 3.1810 in 3 years and CHF 4.8587 in 5 years. Versus the current price CHF 2.885, that implies -40.10% in 1 year, +10.25% in 3 years and +68.39% in 5 years. Forecasts are model-based projections and not guarantees. Use these as scenario inputs around the earnings outcome.

Technical, liquidity and risk signals for RLF.SW stock

Average volume is 41,210.00 shares; today’s relative volume is 1.62, showing above-normal activity. Year high is CHF 4.59 and year low is CHF 1.65, so volatility is material. Key risks include trial failures, dilutive financings, and regulatory delays. Strengths include a diversified pipeline and a strong current ratio that gives short-term liquidity buffer.

Final Thoughts

Key takeaways: RLF.SW stock is trading at CHF 2.885 intraday on the SIX ahead of the 08 Apr 2026 earnings announcement. The immediate move will hinge on clinical updates and any guidance on cash runway or partnerships. Fundamentals show negative EPS (-1.36) and a PE of -2.12, typical for a clinical-stage biotech where value is tied to trial outcomes. Meyka AI rates the stock 64.81/100 (B, HOLD) and the forecast model implies a -40.10% change at 1 year but +68.39% at 5 years, reflecting long-term upside conditional on success. Traders should size positions for volatility and watch volume and company guidance on the earnings date. Remember forecasts are model outputs, not guarantees. For real-time market tools and updates use our AI-powered market analysis platform Meyka AI and review company releases before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.